Phagocytosis inhibition Spleen tyrosine kinase(Syk)-inhibition SOVLEPLENIB (HMPL- 523) Inhibition of macrophage by inhibition NCT05029635 III A Randomized, Double-blind, Persistent / chronic October 2021 of Syk, involved in a signaling cascade to Placebo-controlled Phase 3 ITP / Active Not initiate phagocytosis Clinical Study to Evaluate the recruiting Efficacy and Safety of Sovleplenib (HMPL-523) in Treatment of Primary ITP CEVIDOPLENIB (SIK- NCT04056195 II A Phase 2, Multicenter, Persistent / chronic October 2019 O-703) Randomized, Double-Blind, ITP / Recruiting Placebo-Controlled, Parallel Dose Study to Evaluate the Efficacy and Safety of Oral Cevidoplenib (SKI- O-703), in Patients With Persistent and Chronic ITP Bruton's tyrosine kinase inhibition (iBTK) RILZABRUTINIB Inhibition of macrophage phagocytosis NCT04562766 III A Phase 3, Multicenter, Persistent / chronic December (PRN-1008) by inhibition of BTK, which is Randomized, Double-Blind, ITP 2020 / immediately Placebo Controlled, Parallel- Recruiting downstream from Syk Group Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib (PRN-1008) in Adults and Adolescents With Persistent or Chronic ITP ORELABRUTINIB NCT05020288 I/II A Prospective, Open-label, Persistent / chronic Septembre (ICP-022) Multicenter, Single-armed Study ITP 2021 / of Orelabrutinib (ICP-022) in the Recruiting Treatment of Refractory Primary ITP NCT05232149 II A Randomized, Multi-center, Persistent / chronic February Adaptive Phase 2a/2b Study to ITP 2022 / Evaluate the Efficacy and Safety of Recruiting Orelabrutinib (ICP-022) in Adult Patients With Persistent or Chronic Primary ITP Fc receptor-targeting FcRn inhibition EFGARTIGIMOD Increase antiplatelet IgG1 Fc NCT04225156 III A Phase 3, Multicenter, Open- Newly diagnosed / June 2020 / (ARGX-113) autoantibody fragment label, Long-term Trial to Evaluate persistent / chronic Active not clearance the Safety and Efficacy of ITP recruiting Efgartigimod (ARGX-113) 10 mg/ kg Intravenous in Adult Patients With Primary ITP ROZANOLIXIZUMAB Humanized NCT04200456 III A Phase 3 Multicenter, Double- Persistent / chronic January (UCB-7665) IgG4 Blind, Randomized, Placebo- ITP 2020 / monoclonal Controlled Study to Evaluate the Completed antibody Efficacy, Safety, and Tolerability of Rozanolixizumab (UCB-7665) in Adult Study Participants With Persistent or Chronic Primary ITP BATOCLIMAB (HBM- Fully human NCT04428255 II/III A Randomized, Double-blind, Persistent / chronic July 2020 / 9161) IgG1 Placebo-controlled, Phase 2/3 ITP Recruiting monoclonal Operational Seamless Designed antibody Clinical Study to Evaluate the Efficacy and Safety of Batoclimab (HBM-9161) Weekly Subcutaneous Injection in Patients With Primary ITP Plasma cells maturation/depletion Plasma cell depletion DARATUMUMAB Decrease in Fully human NCT04703621 II A multicenter clinical, open-label Persistent / chronic January antiplatelet IgG1 total dose-escalating phase 2 study ITP, with ≥ 2 2021 / autoantibody monoclonal with safety run-in to explore the therapeutic lines Recruiting production by antibody clinical activity, total dosage, and inhibition of CD38 safety of Daratumumab in adult ITP patients who have not responded adequately or relapsed after corticosteroids and at least one second-line therapy including rituximab and/or TPO-RA (DART study) (continued on next page).